Evidence map›Paper›PMID 29487529›Full record

ArticleFrontiers in pharmacology2018

Nanoliposome-Encapsulated Brinzolamide-hydropropyl-β-cyclodextrin Inclusion Complex: A Potential Therapeutic Ocular Drug-Delivery System.

Fazhan Wang, Xingting Bao, Aiping Fang, Huili Li, Yang Zhou, Yongmei Liu, Chunling Jiang, Jinhui Wu, Xiangrong Song

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Therapeutic applications of nanobiotechnology.Journal of nanobiotechnology · 2023
    Review
  15. Article
  16. Nano-liposomal encapsulation ofFood science & nutrition · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Technological evolution of cyclodextrins in the pharmaceutical field.Journal of drug delivery science and technology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Fazhan WangState Key Laboratory of Biotherapy, Geriatrics and Cancer Center, West China Hospital and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
Xingting BaoState Key Laboratory of Biotherapy, Geriatrics and Cancer Center, West China Hospital and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
Aiping FangState Key Laboratory of Biotherapy, Geriatrics and Cancer Center, West China Hospital and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
Huili LiState Key Laboratory of Biotherapy, Geriatrics and Cancer Center, West China Hospital and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
Yang ZhouState Key Laboratory of Biotherapy, Geriatrics and Cancer Center, West China Hospital and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
Yongmei LiuState Key Laboratory of Biotherapy, Geriatrics and Cancer Center, West China Hospital and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
Chunling JiangState Key Laboratory of Biotherapy, Geriatrics and Cancer Center, West China Hospital and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
Jinhui WuState Key Laboratory of Biotherapy, Geriatrics and Cancer Center, West China Hospital and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
Xiangrong SongState Key Laboratory of Biotherapy, Geriatrics and Cancer Center, West China Hospital and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China.
Sichuan University · CNState Key Laboratory of Biotherapy

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel ocular drug delivery systems (NODDSs) remain to be explored to overcome the anatomical and physiological barriers of the eyes. This study was to encapsulate brinzolamide (BRZ)-hydropropyl-β-cyclodextrin (HP-β-CD) inclusion complex (HP-β-CD/BRZ) into nanoliposomes and investigate its potential as one of NODDS to improve BRZ local glaucomatous therapeutic effect. HP-β-CD/BRZ was firstly prepared to enhance the solubility of poorly water-soluble BRZ. The HP-β-CD/BRZ loaded nanoliposomes (BCL) were subsequently constructed by thin-film dispersion method. After the optimization of the ratio of BRZ to HP-β-CD, the optimal BCL showed an average size of 82.29 ± 6.20 nm, ζ potential of -3.57 ± 0.46 mV and entrapment efficiency (EE) of 92.50 ± 2.10% with nearly spherical in shape. The X-ray diffraction (XRD) confirmed the formation of HP-β-CD/BRZ and BCL. The

Indexed as

brinzolamidecyclodextrininclusion complexintraocular pressurenanoliposomesocular drug delivery

Identifiers

PMID29487529
PMCPMC5816959
OpenAlexW2794022808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.